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824FO-2 Pr imary  S tent lng  Opt imizes  the  Outcome of Women 
With Acute Myocardial Infarction: Results From the 
CADILLAC Trial  
Alexandra J. Lanskv, Cindy Grines, Kartik Deaai, Ecatarina Cristea, Maria Corral, David 
Cox, Susan Gedney, John J. Griffin, Thomas Stuckey, Eulogia Garcia, Barry D. 
Rutherford, Gregg W. Stone, Cardiovascular Research Foundation, New York, New 
York, Lenox Hill Heart and Vascular Institute, New York, New York. 
Background: In the PAMI trial, use of thrombotytic therapy was a predictor of mortality for 
women, whereas pdmary PTCA was associated with significant improvements in short and 
long-term outcome. However, the optimal revascularization strategy for women with AMI 
remains unclear. Methods: We evaluated gender-based outcomes from the CADILLAC 
tdsl, which randomized 2080 pts (1520 men and 562 women) with AMI presenting w/in 12 
hours of symptom onset (exct. cardiogenio shock) to primary PTCA, PTCA+ abciximab, 
stent alone, or stent+abciximab. Results: Women were older (65 vs 58yra, p<0.001), had 
more hypertension (45% vs 29%, p<0.001), diabetes (24% vs 14%, p<0.001), hyperlipi- 
demia (43% vs 36%, pl in 15% vs t0%, p<0.001). By quantitative angiogrephy women 
had smaller vessel sizes (2.84mm vs 3.02mm, p<0.001). Stents were used in 57% and 
abciximab in 53% of cases. The final % diameter stenosis (DS) was similar (18%) in men 
and women, as was the %DS at follow-up (41% vs 39%, p=0.50). Clinical outcome are 
listed in table.Among women, the use of stents was associated with the lowest MACE at 
6months follow-up((OR 0.49) 95%CI [0.32, 0.75], p=0.001). 
Conclusion: Women with acute myocardial infarction undergoing primary intervention have 
higher 30 day and 6 month MACE compared to men, due in part to the higher frequency of 
baseline risk factors. Primary stenting in women as in men is the best revascularization 
strategy for AMI. 
Men Women P Value 
30 day MACE, % 4.6% 9.4% <0.001 
30 day Death, % 1.2% 4.6% <0.001 
30 day TVR, % 2.3% 4.5% 0.104 
6 month MACE,% 11.8% 20.5% <0.001 
6 month Death, % 2.4% 6.4% <0.001 
6 month TVR, % 8.8% 13.5% <0.001 
Restenosis (%) 27.6% 30.2% 0.544 
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824FO-3 Guide Wire Inducable Reopening of the Infarct  Related 
Ar tery  in Pat ients  With Acute  ST -Segment  E levat ion  
Myocardial Infarction Undergoing Pr imary  
Percutaneous Intervention: A Marker of Low Morta l i ty  
Volkhard Kurowski. Dirk P. Killermann, Deapak Jain, Uwe K. Wiegand, Evangelos 
Giannitsis, Ralph Toelg, Franz Hartmann, Hugo A. Katus, Gert Richardt, Medical 
University of Luebeck, Luebeck, German~ 
Background: During primary PCI in AMI the restitution of coronary blood flow may be 
already observed after passage of the culprit lesion with the guide wire and before defi- 
nite angioplasty/stenting. We sought to determine variables associated with such a wire 
inducable reopening (WIRe) of the infarct related artery (IRA) and its prognostic implica- 
tion. 
Methods: 328 consecutive patients (pts.) with acute ST-segment elevation MI undergoing 
primary PCI within 12 hrs after onset of symptoms were enrolled and followed for up to 
1099 (mean 480) days. WIRe was defined as TIMI grade 22 flow visualized in the first 
angiogram after guide wire passage. 
Results: At time of PCI, 90 pts. (27.4%, group I) presented with a spontaneously 
reopened IRA, 56 pts. (17.1%, group II) revealed WIRe, in 165 pat. (50.3%, group III) 
successful reoanalisation (TIMI grade >_.2 flow) was achieved by angioplasty/stenting, and 
in 17 pat. (5.2%, group IV) PCI was ultimately not successful. Cumulative cardiac mortal- 
ity was significantly (p<0.001) different between group I (6.7%), II (3.6%), Ill (13.9%), and 
IV (70.6%). The comparison between pts. with primarily occluded iRA and WIRe and 
those in whom a patent IRA was not observed before balloon dilatation and/or stenting 
(group II vs Ill) revealed significant (<0.05) differences with respect to a positive (>0.1 ng/ 
ml) troponin(TnT) test on admission (29 vs 53%), anterior MI (23 ve 51%) and age (59 vs 
65 yrs), but not with respect to time from onset of symptoms to mechanical reperfusion 
(4.2 vs 5.0 hrs). Glycoprotein lib/Ilia antagonist treatment was less often initiated in 
group II (21 ve 43% in group III, p<0.01). 
Conclusion: Pts. with AMI and WIRe during pdmary PCI have a pronounced low mortal- 
ity rate possibly due to a smaller thrombus load and/or less affected microvascuier flow 
as indicated by a negative TnT test on admission. Thus, WIRe serves as a prognostic 
marker which may help to establish a strategy for adjunctive therapy which is both, ade- 
quate and cost-effective. 
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824FO-4 Can Risk Stretification Using TIMI Score of  Unstab le  
Angina/Non-ST E levat ion  Myocard ia l  In farc t ion  Predict 
Short-Term Outcome After Percutaneoua Coronary 
I n te rvent ion?  
Arlrraeoorna S. Kini. Cristina A. Mitre, Paul Lee, Mazullah Kamran, Michael Kim, Mary E. 
Duffy, Jonathan D. Marmur, Samin K. Sharma, The Mount Sinai Medical Center, New 
York, New York. 
Background: Risk stratification using TIMI score in unstable angina (UA) and non-ST 
elevation myocardial infarction (NSTEMI) for optimal medical management has been 
established using 7 variables: age >65 yrs, significant coronary artery disease (CAD), 
ST-segment changes, rest pain within 24 hrs, aspirin use within 7 days, >_3 CAD risk fac- 
tors, positive cardiac markers. Application of TIMI risk score to predict in-hospital and 
short-term outcome in UNNSTEMI patients undergoing percutaneous coronary interven- 
tion (PCI) has not been studied. 
Methods: We analyzed 2501 consecutive UNNSTEMI patients undergoing PCI from 
July 1999 to May 2001 for in-hospifal and 30-day outcome based on TIMI score: Iow-dek 
0-2, intermediate 3-4, and high-risk 5-7. 
Results: Si~]nificant clinical and procedural variables are: 
Variables Low-rlsk Intermedlat~-dsk Hlgh-rlsk p 
n=964 n=1311 n=181 
Age (yrs) 62.1_+11.8 67.7_+11.4 73_+9.1 <0.0001 
Male sex (%) 70 66 60 0.03 
3-vessel CAD (%) 15 28 39 <0.0001 
ACC/AHA B2/C lesion (%) 79 81 86 0.01 
Pre-PCI GP inhibitor use (%) 15 13 24 <0.0001 
Overall GP inhibitor use (%) 89 85 79 0.0002 
Angiographic/clinical success (%) 97.1/98.4 97.6/98.8 97.2/98.6 NS 
Minor procedural events (%) 9 10 11 0.6 
Peak CK-MB U/L 14.1_+36 14.2±35 21.7_+54 0.07 
Peak troponin I (ng/ml) 3.0-+7.9 2.8_+7.3 6.1_+11.5 <0.001 
Length of stay (days) 2.3_+3.1 3.1_+11.9 3.4_+3.7 <0.0001 
30-day MACE (%) 6.1 5.2 8.5 0.04 
MACE = death, MI (Q wave or CK-MB >3x normal), urgent revascularization 
On multivariate analysis TIMI risk score remains an independent predicto~ for peri-procedural 
enzyme release, in-hospital stay, and 30-dey MACE (2.6 OR, 95% CI 1.8-3.5; p<0.01). 
Conclusion: Increasing TIMI risk score in UNNSTEMI patients undergoing PCI correlates with 
multi vessel CAD, complex coronary lesions, peal-procedural enzyme release, and 30-day out- 
come. However, angiog rap hic/clinical success and procedural events in the ere of stent end GP 
inhibitor use are not different. Therefore, TIMI risk score can be a simple and useful tool to pre- 
dict the in-hospital and 30-day outcome in U/VNSTEMI patients undergoing PCI. 
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824FO-5 Faci l i tated Angioplaaty With Combined ADP P2T 
Receptor  B lockade  and F lb r ino lys i s  fo r  the Treatment  o f  
Acute Myocardial Infarction: Results From the STEP- 
AMI Trial  
Abedelrahim I. Asfour. Adam B. Greenbaum, Thomas M. McFadand, Michelie LeMay, 
Jack A. Painter, Jack A. Painter, Joshua Kieval, Amanda Stebbins, W Douglas Weaver, 
Henry Ford Hospital, Detroit, Michigan. 
Recent studies suggest the feasibility of proceeding with pemutaneous coronary intervention 
(PCI) in the setting of acute myocardial infarction (AMI) with glycopretafo lib/Ilia receptor inhi- 
bition and lower dose fibrinolytic therapy. Our goal was to investigate the feasibility of PCI 
using a novel intravenous ADP P2T receptor antagonist and lower dose fibdnolytic therapy 
for the treatment of AMI. The Safety, ToierabUlty and Effect on Patency in Acute Myocardial 
Infarction (STEP-AMI) trial randomized patients with AMI to receive 1 of 3 doses of AR- 
C6993MX (35, 140 or 280pg/min) along with 50 mg t-PA given over 60 minutes, AR- 
C6993MX 2801~g/min alone, or standard dose t-PA alone. All patients were to undergo 60- 
minute angiography with PCI if necessary or at the discretion of the treating physician. The 
trial was stopped after 101 of 180 planned patients were enrolled. Of 87 patients who under- 
went angiography, PCI was performed in 64 (73.6%). Overall success was achieved in 97% 
of patients with TIMI 3 flow achieved in 86%. Procedural complications were noted in 17 
patients (26.5%) with no difference between those receiving combination therapy and stan- 
dard-dose t-PA (30% vs. 33%, respectively). Through 30 days the incidence of major adveme 
cardiac events was lower in patients undergoing PCI at the time of angiography (see table). 
Facilitated angioplasty appears feasible with combined ADP P2T receptor blockade and 
lower dose fibdnolytic therapy for the treatment of AMI. 
Adverse cardiac events through 30 days 
PCI at time of Angiography No PCI at time of Angiography 
N 64 19 
Death 1 (1.6%) 2 (11.1%) 
Reinfarction 2 (3.2%) 1 (5.9%) 
Urgent Revascularization 2 (3.2%) 1 (5.9%) 
Composite 5 (8%) 4 (2 t %) 
